4 hours agoThe U.S. government purchased 500,000 treatment courses of remdesivir from Gilead at a cost of $3,120 each. This equals $1.56 billion dollars and it is only a 3-month supply for the USA. Europe was essentially locked out of the supply on this first manufacturing round.
Simple math says the annual supply for the USA would be $6.24 billion and once the supply expands and Europe gets to buy then their revenue will probably double to $12.48 billion.
All for a product that Gilead themselves admits:
“Modestly shortened recovery time by four days”
“Did not reduce fatalities”
That is all well and good, but Mesoblast has a product called remestemcel-L which completed a short trial of 12 where 9 lives were saved and they are now running a 300-patient confirming trial which will hopefully produce similar results. [That trial started on May 6th, 2020 and expected to complete in 2 to 4 months.]
What do you suppose the government will do if the results are confirmed and that remestemcel-L will save about 75% of the lives? Will the USA and Europe suddenly decide to buy $12 billion dollars’ worth of product from Mesoblast? I think they will.
LongStock 2 hours ago
What happens to the Meso share price when the government buys out the first manufacturing run of remestemcel-L for $1.5 billion-dollars? If you use a 31 P/E like REGN has would that translate to a $232 share price? A good question.
The cells grow and double in size every week while they are in the Lonza growing trays, wait another week and we could have $3 billion-dollars worth product ready to go.
That enough to get the investment juices flowing.
Excellent proposition!
Gltah
- Forums
- ASX - By Stock
- MSB
- MSB Trading - 2020
MSB Trading - 2020, page-17711
-
- There are more pages in this discussion • 5,450 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
95.5¢ |
Change
0.005(0.53%) |
Mkt cap ! $1.090B |
Open | High | Low | Value | Volume |
95.0¢ | 96.0¢ | 93.5¢ | $2.477M | 2.610M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 14809 | 95.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
95.5¢ | 10582 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 14809 | 0.950 |
6 | 135948 | 0.945 |
10 | 298638 | 0.940 |
7 | 79890 | 0.935 |
7 | 64150 | 0.930 |
Price($) | Vol. | No. |
---|---|---|
0.955 | 10582 | 1 |
0.960 | 39943 | 3 |
0.965 | 15052 | 2 |
0.970 | 42352 | 4 |
0.975 | 14000 | 1 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online